Lee Jones, Rebiotix and Glenn Taylor, Taymount Clinic Discuss Fecal Microbiota Transplant (FMT) AKA Microbiota Restoration Therapy, Research to Clinical, on C diff Radio

cdiffRadioLogoMarch2015Join us on Tuesday, April 7th at 11:00 a.m.  Pacific / 2:00 p.m. Eastern Time

As guests, Ms. Lee Jones, CEO Rebiotix, Inc.  and Glenn Taylor, Microbiologist at Taymount Clinic  discuss

Fecal Microbiota Transplant (FMT) AKA Microbiota Restoration Therapy, Research to Clinical

 

 

Ms. Lee Jones, Founder, President and CEO of Rebiotix Inc, has over thirty years of experience in the medical technology industry in large and small companies and academia. Rebiotix is developing a new category of biologic drugs that use live human-derived organisms to treat disease. Lead candidate RBX2660 (microbiota suspension) is currently undergoing clinical study for recurrent C. diff. infection.

Mr. Glenn Taylor is the Microbiologist at the Taymount Clinic just outside London in the UK. He has spent five years researching the commensal colonization of bacteria in the human digestive system. Listen in as both guests discuss the Fecal or Faecal Microbiota Transplant (FMT),also known as Microbiota Restoration Therapy to treat recurrent C. diff. infections and more – Research to Clinical.

Each C. diff. Spores and More” episode becomes a pod-cast and can be easily accessed through our website:

https://cdifffoundation.org/c-diff-radio/

C. diff. Spores and More” spotlights world renown topic experts, research scientists, healthcare professionals, organization representatives, C. diff. survivors, board members, and their volunteers who are all creating positive changes in the C. diff. community and more.

Through their interviews, the CDF mission will connect, educate, and empower many in over 180 countries.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of Clostridium difficile disease and the need to stratify patients by disease severity.

 

Please join us Tuesdays in listening to the educational episodes of C. diff. Spores and More”

Take our show on the go…………..download a mobile app today

http://www.voiceamerica.com/company/mobileapps